What do prescribers think of biosimilars? - Wikidata - wikimedia - TriplyDB

What do prescribers think of biosimilars?

What do prescribers think of biosimilars?

http://www.wikidata.org/entity/Q37977012

about

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany.Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.

P2860

Q36347183-7B964A4A-2F2B-4F53-9FC4-15B7CEA9D121 Q37387974-0439EB3D-1239-45F2-AA21-80F6A0DD0FE6 Q38223249-3F6EE141-DC21-499E-AC4A-EA341EF4A7A8 Q38708927-2BF1F6D6-6FBD-43E8-B217-6560465536E1 Q38885209-64E889AC-7606-410E-AC03-80834C3A71AF Q39141802-95335CA4-C198-4E0E-B953-F3B12C0E9D29 Q39293869-09A1AA64-E4A9-4514-A29E-C8825EA33727 Q40141879-0697CB9D-E324-4013-8477-7BEA0D8EC631 Q47965968-9ED10DA8-D2BD-441C-A48E-344F82B209B8 Q48256716-2A907E29-3229-497C-A037-1F36F34A1EDD

P2860

What do prescribers think of biosimilars?

http://www.wikidata.org/entity/Q37977012

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

What do prescribers think of biosimilars?

@en

What do prescribers think of biosimilars?

@nl

type

label

What do prescribers think of biosimilars?

@en

What do prescribers think of biosimilars?

@nl

prefLabel

What do prescribers think of biosimilars?

@en

What do prescribers think of biosimilars?

@nl

P1433

Q37977012-075F1B10-98BC-49A9-B994-5AA13EED54AF

P1476

Q37977012-9B740D8B-85D9-43D2-8625-A2968DEDF15D

P2093

Q37977012-5D7705CE-ED0B-464C-AD1D-8BCBAEE478E9

P2860

Q37977012-02AFDF62-004B-4BDF-AF33-782FB1C4EBB9

Q37977012-0E4F299E-F23D-4C68-86DA-BA569075FBF3

Q37977012-26FAF562-D1E8-41B7-B261-0D93CE75EEBD

Q37977012-2902DCBD-7294-474A-9DBE-02A1A14C228E

Q37977012-30AD018E-D7D9-4C50-BB0B-DFC2791ED0FB

Q37977012-3BE0A225-0199-409D-B7AB-01FF2CC8CD2E

Q37977012-4BEDBF57-C0AC-4664-865A-D5B08AC4D0EB

Q37977012-6F0B198A-935D-4DAF-9D0A-D494623ED594

Q37977012-76044099-2966-46B8-8C21-96B935D2ED64

Q37977012-92FD3964-08A6-4AAB-9E0B-432C3B661207

P2888

Q37977012-7FAB0A30-629D-4325-B2D8-C318EA19446D

P304

Q37977012-1907076B-A45D-4131-91FA-59E1007F4475

P31

Q37977012-8C862694-9A2F-4EBF-8065-FAFC3AD41ECE

P356

Q37977012-4C00EA20-2C4D-4A9D-B5FE-8AFEB10A9DB5

P478

Q37977012-E7F515B5-1937-4224-A53A-BAB724434836

P577

Q37977012-CB116C94-24D7-45C4-874A-2062274CEB94

P698

Q37977012-CB1B3F83-5702-48D4-B9BB-8FC1B9450DE5

P356

S11523-011-0193-6

P1433

Targeted oncology

P1476

What do prescribers think of biosimilars?

@en

P2093

M S Aapro

http://www.w3.org/2001/XMLSchema#string

P2860

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Determinants of generic drug substitution in Switzerland.

Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines.

The challenge of biosimilars.

Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint.

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.

Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.

Assessing the bioequivalence of biosimilars The Retacrit case.

P2888

s11523-011-0193-6

P304

S51-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-011-0193-6

http://www.w3.org/2001/XMLSchema#string

P478

7 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22258706

http://www.w3.org/2001/XMLSchema#string